The impact of urate-lowering therapy on kidney function (IMPULsKF)

Authors

DOI:

https://doi.org/10.22141/2307-1257.6.2.2017.102786

Keywords:

urate-lowering therapy, kidney function, hyperuicemia, chronic kidney disease, gout

Abstract

The concept of trial launched in Ukraine in 2017 with POEM design and 36-months duration is presented. It aims to investigate the impact of two target levels of urate-lowering therapy caused by hyperuricemia on kidney function and chronic kidney disease (CKD) progression measured by estimated glomerular filtration rate and albuminuria in 180 patients with gout (n = 90) and with CKD (n = 90). The main current tasks include: 1) evaluation of serum urate acid (SUA) level most potential preserving kidney function; 2) the new onset of gout attacks depending on SUA level, both in gout and CKD objects; 3) safety and side effects of target and ultra-low SUA levels for evidence-based urate-lowering therapy optimal regime in CKD and non-CKD with gout.

Downloads

Download data is not yet available.

References

Downloads

Published

2021-09-09

How to Cite

Ivanov, D. (2021). The impact of urate-lowering therapy on kidney function (IMPULsKF). KIDNEYS, 6(2), 91–93. https://doi.org/10.22141/2307-1257.6.2.2017.102786

Issue

Section

Cover story

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>